Compassionate Use Study of Pergolide in Patients With Parkinson's Disease

• Status: No longer available
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This compassionate use study is designed to monitor safety in patients who have been doing well on pergolide therapy, wish to continue treatment, and have not been able to tolerate alternative treatments.

Details

• Lead Sponsor: Bausch Health Americas, Inc.; Valeant Pharmaceuticals International, Inc.
• Treatments: Pergolide

Criteria

Inclusion Criteria:

• Diagnosed with Parkinson's disease and treated successfully with pergolide in the recent past

• Attempt to taper off pergolide was unsuccessful and patient was unable to change to other forms of therapy for Parkinson's disease

• No evidence of cardiovalvular disease by echocardiogram conducted within 60 days prior

Exclusion Criteria:

• History or current diagnosis of cardiac valvulopathy

• Inability to undergo echocardiograms every 6 months while receiving pergolide

• Hypersensitivity to pergolide or other ergot derivatives